Ionis Pharmaceuticals earnings release, July 29, 2026

Ionis Pharmaceuticals Inc (IONS) · Form 8-K, Item 2.02 · Filed · SEC filing

Ionis reports second quarter 2026 financial results and highlights progress on key programs

- TRYNGOLZA®

(olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome -

- On track to achieve 2026 financial guidance -

CARLSBAD, Calif., July 29, 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2026.

“With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accelerating growth from TRYNGOLZA and our other wholly owned medicines in the quarters and years to come,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “In the second half of this year, we expect multiple important milestones, including approval of zilganersen for Alexander disease, positioning us for our first independent launch from our leading neurology portfolio. We also expect results from the landmark pelacarsen Lp(a) HORIZON cardiovascular outcomes trial and the global launch of bepirovirsen for chronic hepatitis B. With our advancing pipeline and growing commercial momentum, Ionis is on track to deliver accelerating value to patients and all Ionis stakeholders.”

Second Quarter 2026 Summary Financial Results

(1)

:¹

Second Quarter 2026 Financial Highlights

Second Quarter 2026 Financial Results

“Our performance in the first half of this year reflects the strength and resilience of our business. We delivered significantly increased commercial revenue from our independent launches, substantial R&D revenue from multiple partnered medicines and invested in our advancing wholly owned pipeline,” said Elizabeth L. Hougen, chief financial officer of Ionis. “Even with the outcome of the CARDIO-TTRansform study of eplontersen in ATTR-CM, our first-half execution and positive outlook for the second half of the year keep us on track to achieve our 2026 financial guidance. We also remain on track to achieve our goal of cashflow breakeven in 2028 and deliver substantial growth and long-term value-creation.”

Recent Highlights - Wholly Owned Medicines²

Recent Highlights – Partnered Medicines³

Revenue

Ionis’ revenue was comprised of the following:

Commercial revenue for the second quarter and first half of 2026 increased 15% and 27%, respectively, compared to the same periods in 2025. This increase was primarily driven by DAWNZERA product sales. Research and development revenue was also higher in the second quarter and first half of 2026, compared to the same periods in 2025, driven by multiple payments for programs advancing under its R&D collaborations, and excluding the $280 million upfront payment for the global license of sapablursen to Ono Pharmaceutical Co., Ltd. the Company received in the second quarter of 2025.

Operating Expenses

Operating expenses for the second quarter and first half of 2026 increased year over year, in line with expectations, primarily from investments related to the commercialization efforts for TRYNGOLZA and DAWNZERA and launch preparations for zilganersen in Alexander disease, with full-year expenses remaining on track for low-teens percentage growth year-over-year.

Balance Sheet

As of June 30, 2026, Ionis’ cash, cash equivalents and short-term investments decreased to $2.1 billion, compared to $2.7 billion on

December 31, 2025, primarily due to repayment of the 0% convertible notes on April 1, 2026.⁴

Webcast and Other Updates

Management will host a conference call and webcast to discuss Ionis’ second quarter 2026 results at 8:30 a.m. Eastern time on Wednesday, July 29, 2026. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company’s second quarter 2026 earnings slides click here.

Ionis’ Marketed Medicines

TRYNGOLZA®

(olezarsen):

TRYNGOLZA was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG ≥500 mg/dL) and as an adjunct to diet to reduce TG in adults with familial chylomicronemia syndrome (FCS). For more information about TRYNGOLZA, including the full U.S. Prescribing Information, visit tryngolza.com.

DAWNZERA®

(donidalorsen):

DAWNZERA was approved by the U.S. Food and Drug Administration for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. For more information about DAWNZERA, including the full U.S. Prescribing Information, visit dawnzera.com.

WAINUA®

(eplontersen):

WAINUA was approved by the U.S. Food and Drug Administration for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. For more information about WAINUA, including the full U.S. Prescribing Information, visit wainua.com.

For more information about SPINRAZA and QALSODY, visit https://www.spinraza.com/ and https://www.qalsody.com/, respectively. QALSODY is approved under... (truncated) light chain (NfL) observed in patients treated with QALSODY. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).

About Ionis Pharmaceuticals, Inc.

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit

Ionis.com and follow us on

X (Twitter),

LinkedIn and

Instagram.

Financial statements

Income Statement

Three months ended June 30, — Second Quarter 2026 Summary Financial Results (in millions)

Three months ended June 30, – 2026 – (amounts in millions)Three months ended June 30, – 2025 – (amounts in millions)Six months ended June 30, – 2026 – (amounts in millions)Six months ended June 30, – 2025 – (amounts in millions)
Total revenue268452514584
Operating expenses370312734591
Operating expenses on a non-GAAP basis325282645532
Income (loss) from operations-102140-220-7
Income (loss) from operations on a non-GAAP basis-57170-13152

Income Statement

Three months ended June 30, — Ionis’ revenue was comprised of the following: (in millions)

Three months ended June 30, – 2026 – (amounts in millions)Three months ended June 30, – 2025 – (amounts in millions)Six months ended June 30, – 2026 – (amounts in millions)Six months ended June 30, – 2025 – (amounts in millions)
Product sales, net:TRYNGOLZA sales, net5193226
Product sales, net:DAWNZERA sales, net2642
Product sales, net:Total product sales, net31197426
Royalty revenue:SPINRAZA royalties535497102
Royalty revenue:WAINUA royalties16102720
Royalty revenue:Other royalties761012
Royalty revenue:Total royalty revenue7670134134
Royalty revenue:Other commercial revenue12141819
Royalty revenue:Total commercial revenue119103226179
Research and development revenue:Collaborative agreement revenue133337254382
Research and development revenue:WAINUA joint development revenue16123423
Research and development revenue:Total research and development revenue149349288405
Research and development revenue:Total revenue268452514584

Income Statement

Three months ended — (In Millions, Except Per Share Data)

Three months ended – June 30, – 2026 – (unaudited)Three months ended – June 30, – 2025 – (unaudited)Six months ended – June 30, – 2026 – (unaudited)Six months ended – June 30, – 2025 – (unaudited)
Commercial revenue:Product sales, net31197426
Commercial revenue:Royalty revenue7670134134
Commercial revenue:Other commercial revenue12141819
Commercial revenue:Total commercial revenue119103226179
Research and development revenue:Collaborative agreement revenue133337254382
Research and development revenue:WAINUA joint development revenue16123423
Research and development revenue:Total research and development revenue149349288405
Research and development revenue:Total revenue268452514584
Expenses:Cost of sales3466
Expenses:Research, development and patent217217427418
Expenses:Selling, general and administrative15091301167
Expenses:Total operating expenses370312734591
Expenses:Income (loss) from operations-102140-220-7
Other income (expense):Interest expense related to the sale of future royalties-18-19-35-37
Other income (expense):Other income, net634921
Other income (expense):Income (loss) before income tax benefit (expense)-114124-206-23
Other income (expense):Income tax benefit (expense)-1-1
Other income (expense):Net income (loss)-115124-207-23
Other income (expense):Basic net income (loss) per share-0.690.78-1.25-0.15
Other income (expense):Diluted net income (loss) per share-0.690.7-1.25-0.15
Other income (expense):Shares used in computing basic net income (loss) per share165159165159
Other income (expense):Shares used in computing diluted net income (loss) per share165182165159

Income Statement

Three months ended June 30, — (In Millions) (in millions)

Three months ended June 30, – 2026 – (unaudited)Three months ended June 30, – 2025 – (unaudited)Six months ended June 30, – 2026 – (unaudited)Six months ended June 30, – 2025 – (unaudited)
As reported cost of sales according to GAAP3466
Non-GAAP cost of sales3466
As reported research, development and patent expenses according to GAAP217217427418
Excluding compensation expense related to equity awards-25-20-50-40
Non-GAAP research, development and patent expenses192197377378
As reported selling, general and administrative expenses according to GAAP15091301167
Excluding compensation expense related to equity awards-20-10-39-19
Non-GAAP selling, general and administrative expenses13081262148
As reported operating expenses according to GAAP370312734591
Excluding compensation expense related to equity awards-45-30-89-59
Non-GAAP operating expenses325282645532
As reported income (loss) from operations according to GAAP-102140-220-7
Excluding compensation expense related to equity awards-45-30-89-59
Non-GAAP income (loss) from operations-57170-13152
As reported net income (loss) according to GAAP-115124-207-23
Excluding compensation expense related to equity awards and related tax effects-45-30-89-59
Non-GAAP net income (loss)-70154-11836

Balance Sheet

December 31, — (In Millions) (in millions)

June 30, – 2026 – (unaudited)December 31, – 2025
Assets:Cash, cash equivalents and short-term investments2,0552,677
Assets:Contracts receivable5966
Assets:Other current assets378247
Assets:Property, plant and equipment, net155123
Assets:Right-of-use assets232239
Assets:Other assets116172
Assets:Total assets2,9953,524
Full release

Ionis Forward-looking Statements

This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development, technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by

Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.⁵

In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. TRYNGOLZA® is a registered trademark of Ionis Pharmaceuticals, Inc.

DAWNZERA® is a trademark of Ionis Pharmaceuticals, Inc. AKCEA

TM is a trademark of Akcea Therapeutics, Inc. TEGSEDI

TM is a trademark of Akcea Therapeutics, Inc. WAYLIVRA

TM is a trademark of Akcea

Therapeutics, Inc. SPINRAZA® and QALSODY® are registered trademarks of Biogen. WAINUA® is a registered trademark of the AstraZeneca group of companies.

Ionis Investor Contact:

D. Wade Walke, Ph.D.

IR@ionis.com

760-603-2331

Ionis Media Contact:

Hayley Soffer media@ionis.com

760-603-4679⁶

IONIS PHARMACEUTICALS, INC.

SELECTED FINANCIAL INFORMATION

Condensed Consolidated Statements of Operations

(In Millions, Except Per Share Data)⁷

IONIS PHARMACEUTICALS, INC.

Reconciliation of GAAP to Non-GAAP Basis:

Condensed Consolidated Operating Expenses, Income (Loss) From Operations, and Net Income (Loss)

(In Millions)⁸

Reconciliation of GAAP to Non-GAAP Basis

As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP income (loss) from operations, and non-GAAP net income

(loss) were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis’ non-GAAP results is consistent with how Ionis’ management internally evaluates the performance of its operations.⁹

IONIS PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets

(In Millions)¹⁰

Key 2026 Value Driving Events

(1)

# # #¹¹

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Ionis Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.